

GLOBAL LEADERS TRIAL - Comparison of 24-month ticagrelor and 1-month aspirin versus 12-month dual antiplatelet therapy followed by aspirin monotherapy

Purpose: Anti-platelet strategy comparison following drug-eluting stent placement to minimize complications

Trial Design: N = 15,968. Phase 3; ticagrelor 90 mg b.i.d + 1-month aspirin 75mg qd, followed by ticagrelor for 23 months vs 12-month dual antiplatelet therapy followed by aspirin monotherapy for 12 months; 2-year follow-up.

Primary Endpoints: composite of all-cause mortality or non-fatal new MI

Secondary: bleeding

	ticagrelor	aspirin	P value
all-cause mortality or non-fatal new MI	3.81%	4.37%	0.073
bleeding	2.04%	2.12%	0.77

Results: Over 2 years after PCI, ticagrelor + aspirin for 1 month, followed by ticagrelor for 23 months was not better than DAPT for 12 months followed by 12 months of aspirin in preventing all-cause mortality or new Q-wave MI.

